Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(0.98) by 8.16 percent. This is a 38.46 percent decrease over losses of $(0.65) per share from
The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) confirmed Wednesday it had entered into an exclusive partnership with pharmaceuticals company Epsilon Healthcare Limited (ASX: EPN) to access Epsilon’s Manufacturing Practices (GMP) facility in Australia for
SharkNinja Operating LLC, a subsidiary of JS Global (HKEX: 1691.HK) and an innovation leader in the consumer floor care industry, today announced that the U.S. Patent Office has invalidated all of the asserted claims of
Vontier Corporation (“Vontier”) (NYSE:VNT) today announced that it has entered into a $250 million accelerated share repurchase agreement (the “ASR Agreement” or “ASR”) with Citibank,